Search

Your search keyword '"Maieron, R."' showing total 3 results
Start Over Author "Maieron, R." Topic anti-inflammatory agents, non-steroidal
3 results on '"Maieron, R."'

1. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.

Author

Gionchetti P, D'Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, and Campieri M

Subjects
Administration, Topical, Adolescent, Adult, Aged, Biomarkers blood, Blood Sedimentation, Colitis, Ulcerative blood, Colitis, Ulcerative pathology, Colonoscopy, Erythrocyte Count, Female, Follow-Up Studies, Humans, Intestinal Mucosa pathology, Leukocyte Count, Male, Middle Aged, Remission Induction, Retrospective Studies, Safety, Severity of Illness Index, Single-Blind Method, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Beclomethasone administration & dosage, Colitis, Ulcerative drug therapy, Glucocorticoids administration & dosage, Mesalamine administration & dosage
Abstract

Goals: Therapy for active ulcerative colitis (UC) usually involves rectal formulations of corticosteroids (CS), which are characterized by the risk of systemic steroid-related adverse effects., Background: To compare the efficacy and safety of the topically acting CS beclomethasone dipropionate (BDP) versus mesalamine (5-ASA) in the treatment of active UC., Study: Patients with mild to moderate distal active UC were randomized to a 6-week treatment with BDP 3 mg enema o.d. or 5-ASA 1 g enema daily in a single-blind, multicenter, parallel-group, controlled study. The primary efficacy variable was the decrease in Disease Activity Index (DAI) score. Safety variables were adrenal function, monitoring of adverse events, vital signs, and laboratory parameters., Results: A total of 217 patients were enrolled and treated with BDP (n = 111) or 5-ASA (n = 106). A significant decrease in the DAI score (P < 0.05) was observed in both treatment groups, with a clinical remission rate of 36.7% in the BDP group and of 29.2% in the 5-ASA group. Both treatments were well tolerated. No changes from baseline in morning cortisol levels were observed in the BDP group., Conclusions: BDP administered as a rectal enema over a 6-week treatment period was efficacious and safe in patients with active UC, without interference with pituitary adrenal axis.

Published
2005
Full Text
View/download PDF

2. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial

Author

Gionchetti, P., D'Arienzo, A., Rizzello, F., Manguso, F., Maieron, R., Lecis, P. E., Valpiani, D., Iaquinto, G., Annese, V., Balzano, A., Varoli, G., Campieri, M., Bennato, R., Zilli, M., Biedo, F. C., Germana, B., Bove, A., Lombardi, G., Pasquale, L., Andriulli, A., D'Albasio, G., Bagnoli, S., Adamo, S., Desideri, S., Benedetti, G., Sablich, R., Riegler, G., Caserta, L., Belletta, M., Benedetti, A., Ridolfi, F., Blasi, A., Inserra, G., Prada, A., Ferrau, O., Turiano, S., Loriga, P., Muscas, A., Murgia, R., Colombo, E., Canevelli, E., Menardo, G., Dagnino, F., Monica, F., Giordano, M., Torelli, I., Cuoco, D. L., Villa, E., Rigo, G., Bertani, A., Cremonini, C., Minoli, G., Meucci, G., Cattoni, M., P., Gionchetti, D'Arienzo, Agesilao, F., Rizzello, F., Manguso, R., Maieron, P. E., Leci, D., Valpiani, G., Iaquinto, V., Annese, A., Balzano, G., Varoli, M., Campieri, Italian BDP Study, G. r. o. u. p., Gionchetti P, D’Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, and Campieri M.

Subjects
Male, medicine.medical_treatment, Administration, Topical, single-blind randomized controlled trial, Anti-Inflammatory Agents, Colonoscopy, Ulcerative, Gastroenterology, Beclomethasone, Mesalamine, Topical therapy, Ulcerative colitis, Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Biomarkers, Blood Sedimentation, Colitis, Ulcerative, Erythrocyte Count, Female, Follow-Up Studies, Glucocorticoids, Humans, Intestinal Mucosa, Leukocyte Count, Middle Aged, Remission Induction, Retrospective Studies, Safety, Severity of Illness Index, Single-Blind Method, Treatment Outcome, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, distal active ulcerative coliti, medicine.diagnostic_test, Enema, Colitis, Topical, Administration, Corticosteroid, Non-Steroidal, medicine.drug, medicine.medical_specialty, medicine.drug_class, mesalamine, Mesalazine, Internal medicine, Topical treatment, medicine, Adverse effect, business.industry, Beclometasone dipropionate, medicine.disease, Surgery, chemistry, beclomethasone dipropionate, business
Abstract

Therapy for active ulcerative colitis (UC) usually involves rectal formulations of corticosteroids (CS), which are characterized by the risk of systemic steroid-related adverse effects.To compare the efficacy and safety of the topically acting CS beclomethasone dipropionate (BDP) versus mesalamine (5-ASA) in the treatment of active UC.Patients with mild to moderate distal active UC were randomized to a 6-week treatment with BDP 3 mg enema o.d. or 5-ASA 1 g enema daily in a single-blind, multicenter, parallel-group, controlled study. The primary efficacy variable was the decrease in Disease Activity Index (DAI) score. Safety variables were adrenal function, monitoring of adverse events, vital signs, and laboratory parameters.A total of 217 patients were enrolled and treated with BDP (n = 111) or 5-ASA (n = 106). A significant decrease in the DAI score (P0.05) was observed in both treatment groups, with a clinical remission rate of 36.7% in the BDP group and of 29.2% in the 5-ASA group. Both treatments were well tolerated. No changes from baseline in morning cortisol levels were observed in the BDP group.BDP administered as a rectal enema over a 6-week treatment period was efficacious and safe in patients with active UC, without interference with pituitary adrenal axis.

Published
2005

3. Acute gastrointestinal bleeding due to Meckel's diverticulum heterotopic gastric mucosa

Author

Maieron R, Davor Stimac, Avellini C, Zoratti L, Rizzi C, Scott C, Rubinić M, Ca, Beltrami, and Gl, Da Broi

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Anti-Inflammatory Agents, Non-Steroidal, Choristoma, Middle Aged, Meckel Diverticulum, Gastric Mucosa, Child, Preschool, Acute Disease, Humans, Female, Child, Gastrointestinal Hemorrhage, Aged, Retrospective Studies
Abstract

Meckel's diverticulum is the most common congenital anomaly of the gastrointestinal tract occurring in approximately 2% of the population. In our retrospective study, we analyzed 58 surgical specimens of Meckel's diverticulum operated on in our hospital. Heterotopic gastric mucosa was found in ten. Aim of this study was to establish the aetiopathogenesis of inflammation and consequent haemorrhage in Meckel's diverticulum with heterotopic gastric mucosa. Some studies showed that Helicobacter-like bacteria could play an important role in determining local phlogosis in heterotopic gastric mucosa of Meckel's diverticulum, however, none were found in our biopsy specimens. Analyzing patients with acute intestinal haemorrhage (4 out of 10 with heterotopic gastric mucosa) in Meckel's diverticulum a history of previous oral administration of NSAID's was positive in 3 of them. Although in the recent literature there were few case reports on the use of NSAID's and bleeding from Meckel's diverticulum, our results suggest that even short-term use, in small quantities, of NSAID's can play an important role in determining acute bleeding from Meckel's diverticulum with heterotopic gastric mucosa.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results